Pyxis Oncology (PYXS) Common Equity: 2024-2025
Historic Common Equity for Pyxis Oncology (PYXS) over the last 2 years, with Sep 2025 value amounting to $68.8 million.
- Pyxis Oncology's Common Equity fell 55.25% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.8 million, marking a year-over-year decrease of 55.25%. This contributed to the annual value of $120.8 million for FY2024, which is N/A change from last year.
- According to the latest figures from Q3 2025, Pyxis Oncology's Common Equity is $68.8 million, which was down 21.52% from $87.6 million recorded in Q2 2025.
- In the past 5 years, Pyxis Oncology's Common Equity ranged from a high of $184.2 million in Q1 2024 and a low of $68.8 million during Q3 2025.
- Moreover, its 2-year median value for Common Equity was $120.8 million (2024), whereas its average is $126.8 million.
- Data for Pyxis Oncology's Common Equity shows a maximum YoY plummeted of 55.25% (in 2025) over the last 5 years.
- Over the past 2 years, Pyxis Oncology's Common Equity (Quarterly) stood at $120.8 million in 2024, then slumped by 55.25% to $68.8 million in 2025.
- Its Common Equity stands at $68.8 million for Q3 2025, versus $87.6 million for Q2 2025 and $103.1 million for Q1 2025.